Enimmune Corporation (TPEX:6564)
Taiwan · Delayed Price · Currency is TWD 16.15
+0.05 (0.31%)
Aug 4, 2026, 1:41 PM CST
Enimmune Market Cap
Enimmune has a market cap or net worth of 1.15 billion as of August 4, 2026. Its market cap has decreased by -3.92% in one year.
Market Cap
1.15B
Enterprise Value
1.10B
Revenue
48.19M
Ranking
n/a
PE Ratio
n/a
Stock Price
16.15
ChartMarket Cap Chart
Since September 18, 2018, Enimmune's market cap has decreased from 1.33B to 1.15B, a decrease of -13.39%. That is a compound annual growth rate of -1.81%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 4, 2026 | 1.15B | -22.57% |
| Dec 31, 2025 | 1.49B | -17.27% |
| Dec 31, 2024 | 1.80B | -27.21% |
| Dec 29, 2023 | 2.47B | -38.63% |
| Dec 30, 2022 | 4.02B | 69.85% |
| Dec 30, 2021 | 2.37B | -11.74% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 26, 2018 | Upgrade Pro | Upgrade Pro |
| Sep 18, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Advagene Biopharma | 1.41B |
| GenMont Biotech Incorporation | 1.40B |
| NeoCore Technology | 1.34B |
| Abnova (Taiwan) | 1.27B |
| BiOptic | 1.12B |
| LabTurbo Biotech | 1.10B |
| U-Neuron Biomedical | 1.08B |
| Bio Preventive Medicine | 1.06B |